Boston pays off heart patients over Guidant ICD (implantable cardioverter defibrillators) debacle
This article was originally published in Clinica
Executive Summary
Boston Scientific has agreed to fork out $195m to settle charges concerning acquired company Guidant's failure to warn heart patients about potential flaws in its implantable cardioverter defibrillators (ICDs).